{"id":"NCT02105285","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2014-04-07","resultsPosted":"2015-11-17","lastUpdate":"2015-12-28"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"OPC-1085EL ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Carteolol long-acting ophthalmic solution","otherNames":[]}],"arms":[{"label":"OPC-1085EL ophthalmic solution","type":"EXPERIMENTAL"},{"label":"Carteolol long-acting ophthalmic solution","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with carteolol long-acting ophthalmic solution in subjects who are insufficiently responsive to carteolol long-acting ophthalmic solution.","primaryOutcome":{"measure":"Decrease From Baseline in Intraocular Pressure at Week 8 Predose","timeFrame":"Baseline, Week 8 Predose","effectByArm":[{"arm":"OPC-1085EL Ophthalmic Solution","deltaMin":3.5,"sd":null},{"arm":"Carteolol Long-acting Ophthalmic Solution","deltaMin":1.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Conjunctival hyperaemia","Nasopharyngitis","Eye irritation","Eye pain","Ocular hyperaemia"]}}